Fausto Salaffi

Prof. Fausto Salaffi


Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in European journal of pain
Verified
Journal Article
Closed access
FSFausto Salaffi
Fausto Salaffi
ASAndrea Stancati
Andrea Stancati
CSCarlo Alberto Silvestri
Carlo Alberto Silvestri
ACAlessandro Ciapetti
Alessandro Ciapetti
WGWalter Grassi
Walter Grassi

18 March 2009 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
FSFausto Salaffi
Fausto Salaffi
MCMarina Carotti
Marina Carotti
SGStefania Gasparini
Stefania Gasparini
MIMichele Intorcia
Michele Intorcia
WGWalter Grassi
Walter Grassi
The health-related quality of life (HRQL) is an important indicator of the burden of musculoskeletal disease. The Medical Outcome Study Short-Term 36 (SF-36) is the most used tool that evaluates HRQL as a subjective perception about psychological and physical limitations due to an underlying illness. The purpose of this study was to compare the HRQL scores among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) and a selected sample of health people and determine their relationship with measures of clinical condition.

1 August 2005 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
FSFausto Salaffi
Fausto Salaffi
MCMarina Carotti
Marina Carotti
ASAndrea Stancati
Andrea Stancati
WGWalter Grassi
Walter Grassi

1 August 2003 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
FSFausto Salaffi
Fausto Salaffi
GLG Leardini
G Leardini
BCB Canesi
B Canesi
AMA Mannoni
A Mannoni
AFA Fioravanti
A Fioravanti
LPL Punzi
L Punzi

18 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LCLorenzo Cavagna
Lorenzo Cavagna
ETErnesto Trallero-Araguás
Ernesto Trallero-Araguás
FMFederica Meloni
Federica Meloni
Ilaria CavazzanaIlaria Cavazzana
Ilaria Cavazzana
JRJorge Rojas-Serrano
Jorge Rojas-Serrano
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group’s cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The “ex-novo” occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies’ positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.

1 February 2009 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
EFEmilio Filippucci
Emilio Filippucci
MGM. Gutierrez
M. Gutierrez
DGD. Georgescu
D. Georgescu
FSFausto Salaffi
Fausto Salaffi
WGW. Grassi
W. Grassi